MYELOPEROXIDASE AND COENZYME Q10 MODULATED IN THE CHRONIC KIDNEY DISEASE PATIENTS

Area of Science:

• Biochemistry
• Nephrology
• Clinical Chemistry

Background:

• Chronic kidney disease (CKD) is a progressive condition affecting kidney function.
• Biomarkers are crucial for understanding CKD progression and developing targeted therapies.
• Myeloperoxidase (MPO) and Coenzyme Q10 (CoQ10) roles in CKD require further elucidation.

Purpose of the Study:

• To investigate the association of MPO and CoQ10 levels with different stages of CKD.
• To correlate MPO and CoQ10 levels with standard CKD indicators like urea, creatinine, electrolytes, and estimated glomerular filtration rate (eGFR).

Main Methods:

• A case-control study involving 60 male CKD patients and 30 healthy male controls.
• Blood samples were analyzed for MPO and CoQ10 concentrations using Enzyme-linked immunosorbent assay (ELISA).
• Statistical analysis was performed to compare levels between groups and assess correlations.

Main Results:

• Significantly reduced mean levels of MPO (19.9±6.82 ng/ml) and CoQ10 (2.97±0.511 ng/ml) were observed in CKD patients compared to controls (MPO: 42.4±4.98 ng/ml, CoQ10: 7.07±2.41 ng/ml).
• Both MPO and CoQ10 levels demonstrated a significant inverse correlation with CKD progression (i.e., decreased as CKD stage increased).
• A positive correlation was found between serum MPO and CoQ10 levels in CKD patients.

Conclusions:

• MPO and CoQ10 may serve as potential biomarkers for CKD progression.
• Reduced levels of MPO and CoQ10 are associated with advanced stages of chronic kidney disease.
• Further research is warranted to explore the therapeutic potential of targeting MPO and CoQ10 in CKD management.